Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 Feb;39(1):34-9.
doi: 10.1054/bjom.2000.0459.

Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer--a prospective,randomized, placebo-controlled, double-blind study

Affiliations
Clinical Trial

Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer--a prospective,randomized, placebo-controlled, double-blind study

K A Grötz et al. Br J Oral Maxillofac Surg. 2001 Feb.

Abstract

Objective: To study the efficacy of coumarin/troxerutine for the protection of salivary glands and mucosa during irradiation.

Design: Prospective, randomized, placebo-controlled, double-blind trial.

Setting: University hospital, Germany.

Patients: 48 patients who had radiotherapy to the head and neck.

Main outcome measures: Salivary gland scintigraphy and acute side-effects of radiotherapy (Radiation Therapy Oncology Group (RTOG) score).

Results: 23 patients (11 experimental, 12 placebo) completed the study. The global efficacy measure combining scintigraphy and RTOG score favoured the experimental arm (P=0.07). The RTOG score showed significantly fewer acute side-effects of radiation in the experimental arm (P<0.05).

Conclusion: The results suggest that coumarin/troxerutine have a favourable effect in the treatment of radiogenic sialadenitis and mucositis.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources